-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Market Analysis] Since the beginning of this year, pharmaceutical ETFs have attracted much attentio.
Although most of the yields are negative, the enthusiasm of funds for them is still high, which shows that the pharmaceutical sector is still attractive to investor.
Recently, a number of pharmaceutical ETFs have achieved net growth in their share.
The data shows that since July, the share of E Fund CSI 300 Medical and Health ETF has increased by 541 billion shares, the share of Huabao CSI Medical ETF has increased by 847 billion shares, and the share of Cathay CSI Biomedical ETF has increased by 445 million share.
In addition, the share of Tianhong Guozheng Biomedical ETF also achieved a net increase, reaching 232 million share.
While the share of pharmaceutical ETFs has achieved a net increase, a number of pharmaceutical companies have also disclosed semi-annual report.
For example, many of the constituent stocks of CSI Medical have released transcripts, and the overall performance of the companies that have newly disclosed their mid-term performance forecast is outstandin.
Among them, Jiu'an Medical's performance in the first half of this year has greatly improve.
The net profit attributable to shareholders of listed companies is about 11 billion to 15 billion yuan, an increase of 274636% to 281960% over the same period last yea.
The main reason for the increase in performance is the sales of iHealth kit products Driven by growth; Vaccine head company Wantai Bio is expected to achieve a net profit of 5 billion to 75 billion yuan attributable to owners of the parent company in the first half of the year, a year-on-year increase of 246% to 281% compared with the same period last year; in addition, CRO head The performance of some companies is also very stron.
For example, the net profit of Proton shares attributable to shareholders of listed companies is expected to be 188 billion yuan to 207 billion yuan, a year-on-year increase of 455%-465%; The year-on-year growth rates were 283%-306% and 122%-162% respectivel.
It can be said that the entire sector has a high prosperit.
Judging from the current valuation and price-performance ratio of pharmaceutical stocks, the industry generally believes that it is close to the historical bottom, the overall trend is reasonable, and the price-performance ratio of the sector is outstandin.
Looking forward to the market outlook, Industrial Securities pointed out that the improvement of the domestic innovative drug boom and the upward trend of the US stock XBI index are also expected to drive the CXO trac.
The brokerage believes that after the previous adjustment, the current valuation of the CXO sector has fallen back to a low range, and it is recommended to pay attention to the leading clinical CROs that benefit from the prosperity of domestic innovative drug.
Wanhe Securities also stated that as an industry with rigid demand, consumption and growth, medicine has been continuously optimized based on the current domestic epidemic prevention and control measures, and the epidemic has been effectively controlle.
Limited and other situations may achieve rapid recovery, and the industry recovery can be expecte.
It is recommended to pay attention to pharmaceutical R&D outsourcing companies with both growth and certaint.
In addition, Founder Securities believes that the follow-up market of the biopharmaceutical sector is worth looking forward to, and there are two main lines worthy of attentio.
First, neck-stuck technology has benefited from policy-driven import substitution acceleratio.
Including the acceleration of import substitution of high-end medical equipment, the acceleration of import substitution in the high-grade hospital market caused by the centralized procurement of IVD chemiluminescence in Anhui Province + the acceleration of overseas market expansion, and related scientific service.
At the same time, innovation and upgrading have achieved initial results, and they are optimistic about the commercialization of blockbuster varieties of innovative drugs, the centralized procurement of high-barrier specialty generic drugs to increase market share, and the targets related to innovative R&D service.
Second, the demand for consumer medical care has steadily increase.
It is recommended to pay attention to companies with traditional Chinese medicine service capabilities, traditional Chinese medicine brand OTC, vaccine companies with new products in large quantities, and to pay attention to targets whose performance is expected to exceed expectations in the interim report, the valuation is at the bottom and is very cost-effective, including the scale advantage of third-party medical testing services Prominent enterprises, as well as product lines continue to enrich and superimpose the main business recovery targets,et.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyon.
Although most of the yields are negative, the enthusiasm of funds for them is still high, which shows that the pharmaceutical sector is still attractive to investor.
Recently, a number of pharmaceutical ETFs have achieved net growth in their share.
The data shows that since July, the share of E Fund CSI 300 Medical and Health ETF has increased by 541 billion shares, the share of Huabao CSI Medical ETF has increased by 847 billion shares, and the share of Cathay CSI Biomedical ETF has increased by 445 million share.
In addition, the share of Tianhong Guozheng Biomedical ETF also achieved a net increase, reaching 232 million share.
While the share of pharmaceutical ETFs has achieved a net increase, a number of pharmaceutical companies have also disclosed semi-annual report.
For example, many of the constituent stocks of CSI Medical have released transcripts, and the overall performance of the companies that have newly disclosed their mid-term performance forecast is outstandin.
Among them, Jiu'an Medical's performance in the first half of this year has greatly improve.
The net profit attributable to shareholders of listed companies is about 11 billion to 15 billion yuan, an increase of 274636% to 281960% over the same period last yea.
The main reason for the increase in performance is the sales of iHealth kit products Driven by growth; Vaccine head company Wantai Bio is expected to achieve a net profit of 5 billion to 75 billion yuan attributable to owners of the parent company in the first half of the year, a year-on-year increase of 246% to 281% compared with the same period last year; in addition, CRO head The performance of some companies is also very stron.
For example, the net profit of Proton shares attributable to shareholders of listed companies is expected to be 188 billion yuan to 207 billion yuan, a year-on-year increase of 455%-465%; The year-on-year growth rates were 283%-306% and 122%-162% respectivel.
It can be said that the entire sector has a high prosperit.
Judging from the current valuation and price-performance ratio of pharmaceutical stocks, the industry generally believes that it is close to the historical bottom, the overall trend is reasonable, and the price-performance ratio of the sector is outstandin.
Looking forward to the market outlook, Industrial Securities pointed out that the improvement of the domestic innovative drug boom and the upward trend of the US stock XBI index are also expected to drive the CXO trac.
The brokerage believes that after the previous adjustment, the current valuation of the CXO sector has fallen back to a low range, and it is recommended to pay attention to the leading clinical CROs that benefit from the prosperity of domestic innovative drug.
Wanhe Securities also stated that as an industry with rigid demand, consumption and growth, medicine has been continuously optimized based on the current domestic epidemic prevention and control measures, and the epidemic has been effectively controlle.
Limited and other situations may achieve rapid recovery, and the industry recovery can be expecte.
It is recommended to pay attention to pharmaceutical R&D outsourcing companies with both growth and certaint.
In addition, Founder Securities believes that the follow-up market of the biopharmaceutical sector is worth looking forward to, and there are two main lines worthy of attentio.
First, neck-stuck technology has benefited from policy-driven import substitution acceleratio.
Including the acceleration of import substitution of high-end medical equipment, the acceleration of import substitution in the high-grade hospital market caused by the centralized procurement of IVD chemiluminescence in Anhui Province + the acceleration of overseas market expansion, and related scientific service.
At the same time, innovation and upgrading have achieved initial results, and they are optimistic about the commercialization of blockbuster varieties of innovative drugs, the centralized procurement of high-barrier specialty generic drugs to increase market share, and the targets related to innovative R&D service.
Second, the demand for consumer medical care has steadily increase.
It is recommended to pay attention to companies with traditional Chinese medicine service capabilities, traditional Chinese medicine brand OTC, vaccine companies with new products in large quantities, and to pay attention to targets whose performance is expected to exceed expectations in the interim report, the valuation is at the bottom and is very cost-effective, including the scale advantage of third-party medical testing services Prominent enterprises, as well as product lines continue to enrich and superimpose the main business recovery targets,et.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyon.
